These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 9013054

  • 21. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
    Boonkasemsanti W, Reinprayoon D, Pruksananonda K, Niruttisard S, Triratanachat S, Leepipatpaiboon S, Wannakrairot P.
    Hum Reprod; 1996 Oct; 11 Suppl 2():115-23. PubMed ID: 8982753
    [Abstract] [Full Text] [Related]

  • 22. Pregnancy after removal of Norplant implants contraceptive.
    Affandi B, Santoso SS, Djajadilaga, Hadisaputra W, Moeloek FA, Prihartono J, Lubis F, Samil RS.
    Contraception; 1987 Aug; 36(2):203-9. PubMed ID: 3123134
    [Abstract] [Full Text] [Related]

  • 23. Cytokeratins 8, 18 and 19 in endometrial epithelial cells during the normal menstrual cycle and in women receiving Norplant.
    Wonodirekso S, Au CL, Hadisaputra W, Affandi B, Rogers PA.
    Contraception; 1993 Nov; 48(5):481-93. PubMed ID: 7506133
    [Abstract] [Full Text] [Related]

  • 24. Effects of Norplant contraceptive subdermal implants on serum lipids and lipoproteins.
    Otubu JA, Towobola OA, Aisien AO, Ogunkeye OO.
    Contraception; 1993 Feb; 47(2):149-59. PubMed ID: 8449015
    [Abstract] [Full Text] [Related]

  • 25. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women.
    Naessen T, Olsson SE, Gudmundson J.
    Contraception; 1995 Jul; 52(1):35-9. PubMed ID: 8521712
    [Abstract] [Full Text] [Related]

  • 26. Norplant-2 subdermal contraceptive system: experience in Taiwan.
    Lee TY, Yang YS, Tseng LH, Ko TM, Hsu MC, Chuang SM.
    J Formos Med Assoc; 1993 May; 92(5):446-50. PubMed ID: 8104598
    [Abstract] [Full Text] [Related]

  • 27. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A, Brache V, Tejada AS, Cochon L, Alvarez-Sanchez F.
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [Abstract] [Full Text] [Related]

  • 28. Norplant implants in the UK: first year continuation and removals.
    Peers T, Stevens JE, Graham J, Davey A.
    Contraception; 1996 Jun; 53(6):345-51. PubMed ID: 8773421
    [Abstract] [Full Text] [Related]

  • 29. Experience with side effects and health risks associated with Norplant implant use in adolescents.
    Rosenthal SL, Biro FM, Kollar LM, Hillard PJ, Rauh JL.
    Contraception; 1995 Nov; 52(5):283-5. PubMed ID: 8585884
    [Abstract] [Full Text] [Related]

  • 30. A study of adrenal corticol function and its reserve activity in long-acting injectable contraceptive users.
    Amatayakul K, Petpoo W, Ratanawananukul N, Tanthayaphinant O, Tovanabutra S, Suriyanon V.
    Contraception; 1988 May; 37(5):483-92. PubMed ID: 2970367
    [Abstract] [Full Text] [Related]

  • 31. Menstrual bleeding patterns in Norplant-2 implant users.
    Biswas A, Leong WP, Ratnam SS, Viegas OA.
    Contraception; 1996 Aug; 54(2):91-5. PubMed ID: 8842585
    [Abstract] [Full Text] [Related]

  • 32. Effects of levonorgestrel-releasing subdermal contraceptive implants on bone density and bone metabolism.
    Di X, Li Y, Zhang C, Jiang J, Gu S.
    Contraception; 1999 Sep; 60(3):161-6. PubMed ID: 10640160
    [Abstract] [Full Text] [Related]

  • 33. Assessing the acceptability of Norplant contraceptive in four patient populations.
    Dugoff L, Jones OW, Allen-Davis J, Hurst BS, Schlaff WD.
    Contraception; 1995 Jul; 52(1):45-9. PubMed ID: 8521714
    [Abstract] [Full Text] [Related]

  • 34. Characteristics and experiences of American women electing for early removal of contraceptive implants.
    Frank ML, Ditmore JR, Ilegbodu AE, Bateman L, Poindexter AN.
    Contraception; 1995 Sep; 52(3):159-65. PubMed ID: 7587187
    [Abstract] [Full Text] [Related]

  • 35. Use of Norplant contraceptive implants in the immediate postpartum period: safety and tolerance.
    Phemister DA, Laurent S, Harrison FN.
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):175-9. PubMed ID: 7847530
    [Abstract] [Full Text] [Related]

  • 36. The interaction between sex hormone binding globulin and levonorgestrel released from Norplant, an implantable contraceptive.
    Affandi B, Cekan SZ, Boonkasemsanti W, Samil RS, Diczfalusy E.
    Contraception; 1987 Feb; 35(2):135-45. PubMed ID: 3109803
    [Abstract] [Full Text] [Related]

  • 37. Endometrial lymphomyeloid cells in abnormal uterine bleeding due to levonorgestrel (Norplant).
    Clark DA, Wang S, Rogers P, Vince G, Affandi B.
    Hum Reprod; 1996 Jul; 11(7):1438-44. PubMed ID: 8671483
    [Abstract] [Full Text] [Related]

  • 38. Endometrial vasculature in Norplant users.
    Rogers PA.
    Hum Reprod; 1996 Oct; 11 Suppl 2():45-50. PubMed ID: 8982745
    [Abstract] [Full Text] [Related]

  • 39. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B, Zeng T, Wu S, Sun H, Xiao N.
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [Abstract] [Full Text] [Related]

  • 40. Depressive symptoms and Norplant contraceptive implants.
    Westhoff C, Truman C, Kalmuss D, Cushman L, Rulin M, Heartwell S, Davidson A.
    Contraception; 1998 Apr; 57(4):241-5. PubMed ID: 9649915
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.